This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

Additional QNASL® (beclomethasone Dipropionate) Nasal Aerosol Data To Be Presented At Annual Allergy Meeting

Teva Pharmaceutical Industries Ltd. announced today that additional data analyzed from the Phase III clinical program for QNASL ® (beclomethasone dipropionate) Nasal Aerosol will be presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, Texas on February 22-26, 2013. QNASL ® is a nonaqueous or “dry-mist” nasal aerosol corticosteroid that treats seasonal and year-round nasal allergy symptoms in adults and adolescents 12 years of age and older.

Data will be presented at the meeting regarding the efficacy of QNASL ® in treating the symptoms associated with seasonal and perennial allergic rhinitis (SAR and PAR), including the drug’s potential quality of life benefits and sleep quality improvement. Furthermore, the data also demonstrated nasal symptom relief in patients with SAR and PAR who received treatment with QNASL ® 24 hours after dosing.

On March 23, 2012, the U.S. Food and Drug Administration (FDA) approved QNASL ®. The product became available by prescription in April 2012, making it the first marketed nonaqueous or “dry-mist” nasal aerosol product in a category that reports annual sales of $2.5 billion. QNASL ® is delivered as a once-daily, nonaqueous aerosol that uses an environmentally friendly propellant (HFA) and contains a built-in dose counter.

“These studies are important because the impact of allergic rhinitis on a patient’s quality of life is significant. Nasal allergies are often associated with burdensome symptoms such as nasal congestion, sneezing, and itchy and runny nose, which may contribute to disrupted sleep and impaired daytime activities,” said Dr. Eli Meltzer, Senior Associate, Allergy & Asthma Medical and Research Center, A.P.C. and Clinical Professor, Department of Pediatrics, Division of Allergy and Immunology, University of California, San Diego. “These findings reinforce the efficacy of QNASL ® to treat nasal symptoms and to provide sustained relief from burden of allergic rhinitis.”

The following QNASL ® data will be presented during poster sessions on Sunday, February 24 from 9:45 – 10:45 a.m. (CST) in Hall C (street level) of the Henry B. Gonzalez Convention Center at the AAAAI Annual Meeting:

  • #P409: Improvement of Nasal Congestion and Sleep Quality Following Once-Daily Treatment with Beclomethasone Dipropionate Nasal Aerosol in Patients with Seasonal Allergic Rhinitis
  • #P413: Once-Daily Treatment with Beclomethasone Dipropionate Nasal Aerosol Provides Long-Term and Sustained 24-Hour Nasal Symptom Relief in Patients with Perennial Allergic Rhinitis
  • #P414: Once-Daily Treatment with Beclomethasone Dipropionate Nasal Aerosol Effectively Improves the Symptom of Itchy Ear or Palate Associated with Seasonal Allergic Rhinitis
  • #P415: Once-Daily Treatment with Beclomethasone Dipropionate Nasal Aerosol 320 mg Provides 24-Hour Nasal Symptom Relief in Patients with Seasonal Allergic Rhinitis
  • #P144: QNASL ® (beclomethasone dipropionate) Nonaqueous Nasal Aerosol Delivers Softer Sprays Than Aqueous Flonase ®, Nasacort AQ ®, and Nasonex ®

“The data to be presented at AAAAI further explored the safety and efficacy of QNASL ® and demonstrated its ability to benefit patients suffering from seasonal and year-round nasal allergies,” said Tushar Shah, MD, Senior Vice President, Teva Global Respiratory Research and Development. “Teva Respiratory is committed to offering patients treatment options that deliver continued relief of bothersome nasal allergy symptoms and help improve their quality of life.”

ABOUT ALLERGIC RHINITIS

Allergic rhinitis (AR) is a chronic inflammatory disease characterized by symptoms such as sneezing, nasal itch, runny nose and nasal congestion. For many AR patients, nasal congestion or a stuffy nose may be the most frequent and bothersome symptom. According to a recent survey, patients suffer considerable discomfort during allergy attacks, such that nearly two out of five (38 percent) said their discomfort was not tolerable without relief. Based on the available evidence, intranasal corticosteroids are the most effective treatment options for patients with AR.

1 of 4

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,001.22 -38.27 -0.22%
S&P 500 1,988.40 -3.97 -0.20%
NASDAQ 4,538.5510 +6.4470 0.14%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs